menu
    • menu
    [{"orgOrder":0,"company":"Polpharma","sponsor":"Pikralida biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"POLAND","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"PKL-021","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Polpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Polpharma \/ Pikralida biopharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Polpharma \/ Pikralida biopharmaceutical"},{"orgOrder":0,"company":"Polpharma","sponsor":"Ryvu Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"RVU120","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Polpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Polpharma \/ Ryvu Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Polpharma \/ Ryvu Therapeutics"},{"orgOrder":0,"company":"Polpharma","sponsor":"Ziololek","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Linseed Oil","moa":"","graph1":null,"graph2":null,"graph3":"Polpharma","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Polpharma \/ Polpharma","highestDevelopmentStatusID":null,"companyTruncated":"Polpharma \/ Polpharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Polpharma

    Menu

    Polpharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Polpharma

                            Poland
                            DCAT Week
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothPolpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

                            Lead Product(s) : Flaxseed

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Ziololek

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Polpharma Acquires Ziołolek

                            Details : Through the acquisition, Polpharma enhanced its portfolio of OTC & dermatology products, including Linomag (linseed oil), which is indicated for treating skin conditions such as eczema & intertrigo.

                            Brand Name : Linomag

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 01, 2024

                            Lead Product(s) : Flaxseed

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Ziololek

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Polpharma CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Polpharma

                            Poland
                            DCAT Week
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothPolpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

                            Lead Product(s) : RVU120

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ryvu Therapeutics

                            Deal Size : $1.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ryvu Therapeutics Enters into Two Agreements with Zakłady Farmaceutyczne Polpharma S.A. in the Area of RVU120...

                            Details : RVU120 is a selective, first-in-class dual CDK8/CDK19 kinase inhibitor that has shown signs of clinical activity in treated patients, as well as efficacy in numerous in vitro and in vivo models of hematologic malignancies and solid tumors.

                            Brand Name : RVU120

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 06, 2023

                            Lead Product(s) : RVU120

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ryvu Therapeutics

                            Deal Size : $1.0 million

                            Deal Type : Agreement

                            Polpharma CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Polpharma

                            Poland
                            DCAT Week
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothPolpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

                            Lead Product(s) : PKL-021

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Pikralida biopharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Polpharma Partners with Pikralida Biopharmaceutical Start-Up

                            Details : The partnership involves manufacturing of the drug substance of the clinical candidate PKL-021, needed to support the preclinical research program and the production of an investigational medicinal product for the phase one clinical trial.

                            Brand Name : PKL-021

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 19, 2022

                            Lead Product(s) : PKL-021

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Pikralida biopharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Polpharma CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth